ROYAL GROUP(SZ:002329)2023-10-30 16:00Financial Performance - The company's revenue for Q3 2023 was CNY 749,980,574.80, an increase of 1.66% year-on-year, while the revenue for the year-to-date period reached CNY 2,567,507,636.63, up 24.86% compared to the same period last year[4]. - Total operating revenue for Q3 2023 reached CNY 2,567,507,636.63, an increase of 24.9% compared to CNY 2,056,234,627.19 in the same period last year[26]. - Total operating costs for Q3 2023 were CNY 2,652,015,786.54, up 24.3% from CNY 2,131,554,189.63 in Q3 2022[26]. - Net profit for Q3 2023 was CNY 181,066,012.13, a significant increase from CNY 61,959,309.15 in Q3 2022, representing a growth of 192.5%[27]. - Earnings per share for Q3 2023 were CNY 0.2088, compared to CNY 0.0688 in the same quarter last year, reflecting a substantial increase[28]. Profitability and Loss - The net profit attributable to shareholders for Q3 2023 was a loss of CNY 37,872,689.21, a decrease of 1.18% year-on-year, but the year-to-date net profit was CNY 174,907,988.65, reflecting a significant increase of 203.41%[4]. - The company reported an investment income of CNY 224,651,888.39 for Q3 2023, compared to CNY 1,930,458.10 in the same period last year[27]. - The company's management expenses rose by 68.56% year-on-year, mainly due to the implementation of a restricted stock incentive plan and the consolidation of additional subsidiaries[13]. Cash Flow - The company's cash flow from operating activities for the year-to-date period was CNY 176,070,717.87, a remarkable increase of 3,865.14%[4]. - The net cash flow from operating activities surged by 3,865.14% year-on-year, mainly driven by an increase in cash received from sales of goods and services[16]. - The net cash flow from investing activities rose by 31.88% year-on-year, attributed to increased cash received from investment recoveries and a decrease in cash paid for fixed assets and intangible assets[16]. - The net cash flow from financing activities decreased by 85.98% year-on-year, primarily due to a reduction in cash received from borrowings and other financing-related cash[16]. - The net increase in cash and cash equivalents dropped by 156.07% year-on-year, mainly due to the decline in cash flow from financing activities[16]. Assets and Liabilities - Total assets at the end of Q3 2023 were CNY 5,349,754,126.03, down 9.24% from the end of the previous year[5]. - Total liabilities for Q3 2023 were CNY 3,466,152,681.09, a decrease from CNY 3,957,783,187.65 in the previous period[24]. - The company's total current assets as of September 30, 2023, amounted to ¥2,303,547,331.62, compared to ¥2,246,462,575.12 at the beginning of the year[22]. - The company's long-term equity investments increased to ¥961,570,247.79 as of September 30, 2023, from ¥948,547,056.80 at the beginning of the year[22]. Shareholder Information - As of September 30, 2023, the total number of ordinary shareholders was 67,565[18]. - The largest shareholder, Huang Jiadi, holds 24.78% of the shares, amounting to 215,323,388 shares, with 61,780,000 shares pledged[18]. Research and Development - Research and development expenses increased by 260.86% year-on-year, driven by intensified investment in water buffalo embryo biotechnology and related fields[12]. - Research and development expenses for Q3 2023 were CNY 34,431,552.70, down from CNY 61,305,799.56 in Q3 2022, indicating a reduction in R&D investment[27]. Other Income - Other income increased by 50.42% year-on-year, primarily due to an increase in government subsidies received during the reporting period[14]. - The company achieved an investment income of CNY 211,270,607.43 from the transfer of 32.8996% equity in its subsidiary, reflecting a substantial increase in investment returns[7]. Operating Expenses - The company's operating expenses increased by 31.02% year-on-year, primarily due to higher consulting service fees and other operating expenses[15].